» Articles » PMID: 29099913

Trends in the San Francisco Human Immunodeficiency Virus Epidemic in the "Getting to Zero" Era

Overview
Journal Clin Infect Dis
Date 2017 Nov 4
PMID 29099913
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: San Francisco has launched interventions to reduce new human immunodeficiency virus (HIV) infections and HIV-associated morbidity and mortality during the San Francisco "Getting to Zero" era. We measured recent changes in HIV care indicators to assess the success of these interventions.

Methods: San Francisco residents with newly diagnosed HIV infection, diagnosed from 2009 to 2014, were included. We measured temporal changes from HIV diagnosis to (1) linkage to care in within ≤3 months, (2) initiation of antiretroviral therapy (ART) within ≤12 months, (3) viral suppression within ≤12 months, (4) development of AIDS within ≤3 months, (5) death within ≤12 months, and (6) retention in care 6-12 months after linkage. Kaplan-Meier analyses stratified by year of HIV diagnosis measured time from diagnosis to linkage, ART initiation, viral suppression, AIDS, and death.

Results: Overall, the number of new diagnoses declined from 473 in 2009 to 329 in 2014. The proportion of new diagnoses among men (P = .005), Latinos and Asian/Pacific Islanders (P = .02), and men who have sex with men (P = .003) increased. ART initiation and viral suppression ≤12 months after diagnosis increased (P < .001), while the proportion with AIDS diagnosed ≤3 months after HIV diagnosis declined (P < .001). Time to ART initiation and time to viral suppression were significantly shorter in more recent years of diagnosis (P < .001). Time from HIV to AIDS diagnosis was significantly longer in more recent years (P < .001). Retention in care did not significantly change.

Conclusions: In San Francisco new HIV diagnoses have declined and HIV care indicators have improved during the Getting to Zero era. Continued success requires attention to vulnerable populations and monitoring to adjust programmatic priorities.

Citing Articles

Preparing for the Implementation of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis Within the Brazilian Public Health System (ImPrEP CAB Brasil): Qualitative Study.

Pimenta M, Torres T, Hoagland B, Cohen M, Mann C, Jalil C JMIR Public Health Surveill. 2024; 10:e60961.

PMID: 39446416 PMC: 11544328. DOI: 10.2196/60961.


Sexual behaviour and STIs among MSM living with HIV in the PrEP era: the French ANRS PRIMO cohort study.

Baltes V, de Boissieu P, Champenois K, Luan L, Seng R, Essat A J Int AIDS Soc. 2024; 27(3):e26226.

PMID: 38462760 PMC: 10935706. DOI: 10.1002/jia2.26226.


Interruptions in treatment among adults on anti-retroviral therapy before and after test-and-treat policy in Tanzania.

Mbatia R, Mtisi E, Ismail A, Henjewele C, Moshi S, Christopher A PLoS One. 2023; 18(11):e0292740.

PMID: 37967039 PMC: 10651022. DOI: 10.1371/journal.pone.0292740.


Comparison of Immunological and Virological Recovery with Rapid, Early, and Late Start of Antiretroviral Treatment in Naive Plwh: Real-World Data.

Sarigul Yildirim F, Candevir A, Akhan S, Kaya S, Cabalak M, Ersoz G Int J Gen Med. 2023; 16:1867-1877.

PMID: 37213471 PMC: 10195690. DOI: 10.2147/IJGM.S393370.


Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.

Grinsztejn B, Torres T, Hoagland B, Moreira Jalil E, Moreira R, OMalley G JMIR Public Health Surveill. 2023; 9:e44961.

PMID: 37074775 PMC: 10157454. DOI: 10.2196/44961.


References
1.
Grant R, Anderson P, McMahan V, Liu A, Amico K, Mehrotra M . Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14(9):820-9. PMC: 6107918. DOI: 10.1016/S1473-3099(14)70847-3. View

2.
. Vital signs: HIV prevention through care and treatment--United States. MMWR Morb Mortal Wkly Rep. 2011; 60(47):1618-23. View

3.
Rebeiro P, Gange S, Horberg M, Abraham A, Napravnik S, Samji H . Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS One. 2016; 11(1):e0146119. PMC: 4708981. DOI: 10.1371/journal.pone.0146119. View

4.
McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 387(10013):53-60. PMC: 4700047. DOI: 10.1016/S0140-6736(15)00056-2. View

5.
Raymond H, Chen Y, Ick T, Scheer S, Bernstein K, Liska S . A new trend in the HIV epidemic among men who have sex with men, San Francisco, 2004-2011. J Acquir Immune Defic Syndr. 2013; 62(5):584-9. DOI: 10.1097/QAI.0b013e318285febf. View